探讨急性心肌梗死合并心力衰竭应用替罗非班及重组人脑利钠肽的临床观察

摘要

Objective To investigate the clinical effect of tirofiban and recombinant human brain natriuretic peptide for the treatment of patients with acute myocardial infarction complicated with heart failure.Methods In our hospital from September 2013 to August 2015, 168 cases of patients with AMI-HF were divided into two groups. The control group and the research group had 84 cases. AMI-HF baseline treatment was used in the two groups. The control group increased urokinase thrombolytic therapy, the study group used tirofiban and treatment with recombinant human brain natriuretic peptide. The adverse reactions and treatment of the two groups were compared and analyzed.ResultsThe effective rate of clinical treatment in the study group was 96.43%, and the effective rate of the control group was 83.33%. Conclusion Acute myocardial infarction complicated with heart failure patients accept for the effect of tirofiban and recombinant human brain natriuretic peptide in patients with relatively good, with high security.%目的：探讨替罗非班和重组人脑利钠肽治疗急性心肌梗死合并心衰患者的临床效果。方法选取2013年9月～2015年8月我院收治的168例AMI-HF患者进行了分组研究，对照组和研究组，每组各84例。两组患者均采用AMI-HF基线治疗。对照组增加尿激素酶溶栓治疗，研究组采用替罗非班及重组人脑利钠肽治疗。比较分析两组患者的不良反应和治疗情况。结果研究组患者的临床治疗有效率为96.43%，对照组的临床治疗有效率为83.33%。结论采用替罗非班及重组人脑利钠肽治疗急性心肌梗死合并心衰患者效果显著，具有较高的安全性。